drugset
drugset / Trial / NCT00920595

Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors

NCT00920595 ↗

Phase 1 Completed 26 enrolled Cephalon
NaSingle-groupOpen-labelTreatment

Summary

An open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 as single-agent therapy and as combination therapy with temozolomide in patients with advanced solid tumors.

Timeline

Start
2009-06
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject CEP-9722 Small molecule 150 mg —

Indications

cancer